Mupina (Mupirocin)

Mupirocin is a topical antibacterial indicated for conditions involving nasal colonisation by susceptible bacteria.

• Nasal carriage of Staphylococcus aureus: reduces bacterial load in the anterior nares, aiding infection control.
• MRSA colonisation: eradicates methicillin‑resistant Staphylococcus aureus from the nasal passages, lowering transmission risk.
• Pre‑surgical decolonisation: applied before operative procedures to decrease postoperative wound infection rates associated with nasal flora.
• Healthcare‑associated outbreak control: used in institutional settings to limit spread of staphylococcal infections among patients and staff.

• Mupirocin inhibits bacterial isoleucyl‑tRNA synthetase, an enzyme essential for attaching isoleucine to its corresponding tRNA during protein synthesis. By blocking this step, the drug prevents the formation of functional bacterial proteins, leading to a bacteriostatic effect against susceptible Gram‑positive organisms, particularly Staphylococcus species.

Mupirocin is generally well tolerated, but local and systemic reactions can occur.

Common Side Effects

• Nasal irritation: mild burning or stinging at the application site.
• Itching: localized pruritus within the nostrils.
• Dryness: sensation of dryness in the nasal mucosa.
• Sneezing: transient increase in sneezing episodes.
• Headache: mild headache reported by some users.

Serious or Rare Side Effects

• Allergic contact dermatitis: redness, swelling, or rash at the site.
• Anaphylaxis: rare systemic hypersensitivity reaction requiring immediate medical attention.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Persistent nasal ulceration: prolonged use may lead to mucosal breakdown.
• Systemic infection: unlikely but possible if the barrier is compromised.

Before using Mupina, consider the following safety measures.

• Allergy assessment: avoid if known hypersensitivity to mupirocin or related compounds.
• Open wounds: do not apply to broken skin or mucosa to prevent systemic absorption.
• Concomitant nasal sprays: evaluate need for concurrent use to avoid masking infection signs.
• Pediatric use: use only under medical supervision in children.
• Pregnancy and lactation: discuss potential risks with a healthcare professional.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Mupirocin may interact with other agents, though systemic interactions are limited.

Major Interactions (Avoid)

• Concurrent topical antibiotics: may increase risk of bacterial resistance.
• Systemic antibiotics with overlapping spectrum: may reduce overall effectiveness of each agent.

Moderate Interactions (Monitor Closely)

• Nasal corticosteroids: may mask signs of infection, requiring close monitoring.
• Immunosuppressive therapy: heightened vigilance for secondary infections.
• Antifungal nasal preparations: assess for additive local irritation.